CLAIMS

1. The use of an amorphous solid dispersion dosage form comprising *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in the manufacture of a medicament for the treatment of local or metastatic brain cancer that is caused by ErbB2 over-expression or amplification, wherein the use is after previous treatment for brain cancer.

2. The use of Claim 1, wherein the dispersion polymer is selected from the group consisting of vinylpyrrolidine vinylacetate copolymer, methylacrylic acid methyl methacrylate copolymer, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose, and mixtures thereof.

3. The use of Claims 1 or 2, wherein the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is in the form of a tablet.

4. The use of any one of Claims 1 to 3, wherein the use is in combination with another therapeutic agent.

5. The use of Claim 4, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel.

6. The use of Claim 1, wherein the previous treatment for brain cancer is selected from surgery, radiation therapy and chemotherapy or mixtures thereof.

7. The use of Claim 1, wherein the previous treatment for brain cancer is selected from surgery, conventional external radiation therapy, three-dimensional conformal radiation therapy, intensity modulated radiation therapy, stereotactic radiosurgery, fractionated stereotactic radiation therapy, proton radiation therapy, internal or implant radiation therapy, temozolomide, bevacizumab, carmustine, lomustine, procarbazine, vincristine, tumor treating fields therapy, everolimus, procarbazine, lomustine, cisplatin, carboplatin and methotrexate or mixtures thereof.

8. The use of any one of Claims 1 to 7, wherein about 550 to about 650 mg twice per day of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is used.

9. The use of an amorphous solid dispersion dosage form comprising *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in the manufacture of

a medicament for the treatment of local or metastatic brain cancer that is caused by ErbB2 over-expression or amplification, wherein the use is after previous treatment for breast cancer.

10. The use of Claim 9, wherein the dispersion polymer is selected from the group consisting of vinylpyrrolidine vinylacetate copolymer, methylacrylic acid methyl methacrylate copolymer, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose, and mixtures thereof.

11. The use of Claims 9 or 10, wherein the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is in the form of a tablet.

12. The use of any one of Claims 9 to 11, wherein the use is in combination with another therapeutic agent.

13. The use of Claim 12, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel.

14. The use of Claim 9, wherein the previous treatment for breast cancer is selected from surgery, sentinel lymph node biopsy followed by surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy.

15. The use of Claim 9, wherein the previous treatment for breast cancer is selected from lumpectomy, partial mastectomy, segmental mastectomy, total mastectomy, modified radical mastectomy, external radiation, internal radiation, methotrexate, paclitaxel albumin-stabilized nanoparticle formulation, ado-trastuzumab emtansine, doxorubicin, fluorouracil, everolimus, anastrozole, exemestane, capecitabine, cyclophosphamide, docetaxel, epirubicin, exemestane, toremifene, fulvestrant, letrozole, gemcitabine, trastuzumab, ixabepilone, lapatinib, tamoxifen, pertuzumab and toremifene, or mixtures thereof.

16. The use of any one of Claims 9 to 15, wherein about 550 to about 650 mg twice per day of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is used.

17. The use of (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol in the manufacture of a medicament for the treatment of local or metastatic brain cancer that is caused by ErbB2 over-expression or amplification, wherein the use is after previous treatment for brain cancer.

18. The use of Claim 17, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is in the form of an oral dosage form.

19. The use of Claims 17 or 18, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is a solid dispersion dosage form.

20. The use of Claim 19, wherein the solid dispersion dosage form contains a dispersion polymer selected from the group consisting of vinylpyrrolidine vinylacetate copolymer, methylacrylic acid methyl methacrylate copolymer, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose, and mixtures thereof.

21. The use of any one of Claims 17 to 20, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is in the form of a tablet.

22. The use of any one of Claims 17 to 21, wherein the use is in combination with another therapeutic agent.

23. The use of Claim 22, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel.

24. The use of Claim 17, wherein the previous treatment for brain cancer is selected from surgery, radiation therapy and chemotherapy or mixtures thereof.

25. The use of Claims 17, wherein the previous treatment for brain cancer is selected from surgery, conventional external radiation therapy, three-dimensional conformal radiation therapy, intensity modulated radiation therapy, stereotactic radiosurgery, fractionated stereotactic radiation therapy, proton radiation therapy, internal or implant radiation therapy, temozolomide, bevacizumab, carmustine, lomustine, procarbazine, vincristine, tumor treating fields therapy, everolimus, procarbazine, lomustine, cisplatin, carboplatin and methotrexate or mixtures thereof.

26. The use of any one of Claims 17 to 25, wherein about 25 to about 1800 mg per day of (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is used.

27. The use of (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol in the manufacture of a medicament for the treatment of local or metastatic brain cancer that is

caused by ErbB2 over-expression or amplification, wherein the use is after previous treatment for breast cancer.

28. The use of Claim 27, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is in the form of an oral dosage form.

29. The use of Claims 27 or 28, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is a solid dispersion dosage form.

30. The use of Claim 29, wherein the solid dispersion dosage form contains a dispersion polymer selected from the group consisting of vinylpyrrolidine vinylacetate copolymer, methylacrylic acid methyl methacrylate copolymer, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose, and mixtures thereof.

31. The use of any one of Claims 27 to 30, wherein the (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is in the form of a tablet.

32. The use of any one of Claims 27 to 31, wherein the use is in combination with another therapeutic agent.

33. The use of Claim 32, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel.

34. The use of Claim 27, wherein the previous treatment for breast cancer is selected from surgery, sentinel lymph node biopsy followed by surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy.

35. The use of Claim 27, wherein the previous treatment for breast cancer is selected from lumpectomy, partial mastectomy, segmental mastectomy, total mastectomy, modified radical mastectomy, external radiation, internal radiation, methotrexate, paclitaxel albumin-stabilized nanoparticle formulation, ado-trastuzumab emtansine, doxorubicin, fluorouracil, everolimus, anastrozole, exemestane, capecitabine, cyclophosphamide, docetaxel, epirubicin, exemestane, toremifene, fulvestrant, letrozole, gemcitabine, trastuzumab, ixabepilone, lapatinib, tamoxifen, pertuzumab and toremifene, or mixtures thereof.

36. The use of any one of Claims 27 to 35, wherein about 25 to about 1800 mg per day of (2-((4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)amino)-4-methyl-4,5-dihydrooxazol-4-yl)methanol is used.